ZNF92

Summary

ZNF92 (zinc finger protein 92, HGNC:13168) is a protein-coding gene on chromosome 7q11.21, encoding Zinc finger protein 92 (Q03936). May be involved in transcriptional regulation.

Predicted to enable DNA-binding transcription factor activity, RNA polymerase II-specific and RNA polymerase II cis-regulatory region sequence-specific DNA binding activity. Predicted to be involved in regulation of DNA-templated transcription. Predicted to be located in nucleus.

Source: NCBI Gene 168374 — RefSeq curated summary.

At a glance

• Clinical variants (ClinVar): 87 total
• MANE Select transcript: NM_152626

Identifiers

Gene identifiers

Field	Value
HGNC ID	HGNC:13168
Approved symbol	ZNF92
Name	zinc finger protein 92
Location	7q11.21
Locus type	gene with protein product
Status	Approved
Aliases	HPF12, TF12
Ensembl gene	ENSG00000146757
Ensembl biotype	protein_coding
OMIM	603974
Entrez	168374

Gene structure

Transcript identifiers

Ensembl transcripts: 5 — 4 protein_coding, 1 retained_intron

ENST00000328747, ENST00000357512, ENST00000431504, ENST00000450302, ENST00000488849

RefSeq mRNA: 5 — MANE Select: NM_152626 NM_001287532, NM_001287533, NM_001287534, NM_007139, NM_152626

CCDS: CCDS34646, CCDS47596, CCDS75608, CCDS75609

Canonical transcript exons

ENST00000328747 — 4 exons

Exon	Start	End
ENSE00000000232	65373855	65374000
ENSE00002440765	65387902	65388028
ENSE00003640453	65388806	65388901
ENSE00003670691	65398341	65401136

Expression profiles

Bgee: expression breadth ubiquitous, 250 present calls, max score 89.52.

FANTOM5 (CAGE): breadth ubiquitous, TPM avg 25.0898 / max 474.9734, expressed in 1754 samples.

FANTOM5 promoters (3 alternative TSS)

Promoter ID	TPM avg	Samples expressed
78834	13.4186	1696
78835	11.1565	1466
204460	0.5147	271

Top tissues by expression

263 total, by Bgee expression score (0-100, higher = more expressed):

Tissue	Anatomy ID	Expression score	Quality
endothelial cell	CL:0000115	89.52	silver quality
cortical plate	UBERON:0005343	89.49	gold quality
ganglionic eminence	UBERON:0004023	89.43	gold quality
primordial germ cell in gonad	CL:0000670 ∩ UBERON:0000991	87.89	gold quality
epithelial cell of pancreas	CL:0000083	86.18	silver quality
ventricular zone	UBERON:0003053	85.43	gold quality
amniotic fluid	UBERON:0000173	84.57	gold quality
pigmented layer of retina	UBERON:0001782	84.19	gold quality
bone marrow	UBERON:0002371	82.79	gold quality
oocyte	CL:0000023	82.69	gold quality
oviduct epithelium	UBERON:0004804	82.17	gold quality
adrenal tissue	UBERON:0018303	82.01	gold quality
male germ line stem cell (sensu Vertebrata) in testis	CL:0000089 ∩ UBERON:0000473	81.98	gold quality
lymph node	UBERON:0000029	81.05	gold quality
buccal mucosa cell	CL:0002336	80.57	gold quality
bone marrow cell	CL:0002092	80.31	gold quality
epithelium of mammary gland	UBERON:0003244	80.06	gold quality
mammary duct	UBERON:0001765	80.02	gold quality
epithelium of nasopharynx	UBERON:0001951	79.93	gold quality
thymus	UBERON:0002370	79.72	gold quality
islet of Langerhans	UBERON:0000006	79.65	gold quality
esophagus squamous epithelium	UBERON:0006920	79.65	gold quality
calcaneal tendon	UBERON:0003701	79.35	gold quality
secondary oocyte	CL:0000655	78.75	gold quality
leukocyte	CL:0000738	78.50	gold quality
monocyte	CL:0000576	78.17	gold quality
palpebral conjunctiva	UBERON:0001812	77.90	gold quality
thoracic mammary gland	UBERON:0005200	77.61	gold quality
Brodmann (1909) area 46	UBERON:0006483	77.60	gold quality
endometrium	UBERON:0001295	77.53	gold quality

Single-cell (SCXA)

Detected in 1 experiment(s), a significant marker in 0.

Experiment	Marker?	Max mean expression
E-ANND-3	no	2.66

Regulation

Is transcription factor: no

miRNA regulators (miRDB)

80 targeting ZNF92, top 30 by miRDB confidence (max_score; target_count = how many genes the miRNA targets in total — lower means more specific):

miRNA	Max score	Avg score	miRNA target_count
HSA-MIR-5011-5P	100.00	83.46	5820
HSA-MIR-190A-3P	100.00	80.35	5520
HSA-LET-7A-3P	100.00	74.03	3932
HSA-LET-7B-3P	100.00	74.08	3913
HSA-LET-7F-1-3P	100.00	74.02	3928
HSA-MIR-98-3P	100.00	74.08	3907
HSA-MIR-3064-3P	100.00	70.09	1254
HSA-MIR-3613-3P	100.00	76.36	7965
HSA-MIR-4775	99.98	75.00	6394
HSA-MIR-3065-5P	99.97	71.56	3281
HSA-MIR-590-3P	99.96	74.34	6478
HSA-MIR-548AT-5P	99.96	70.83	2666
HSA-MIR-4666A-3P	99.96	71.71	3434
HSA-MIR-1236-3P	99.94	68.04	1695
HSA-MIR-335-3P	99.93	73.36	4958
HSA-MIR-515-5P	99.92	69.82	2343
HSA-MIR-519E-5P	99.92	69.62	2358
HSA-MIR-3119	99.92	71.34	2390
HSA-MIR-1297	99.91	73.41	3162
HSA-MIR-629-3P	99.85	67.99	1875
HSA-MIR-4698	99.84	71.41	4303
HSA-MIR-4307	99.82	70.45	3374
HSA-MIR-548AJ-5P	99.78	71.12	3085
HSA-MIR-548F-5P	99.78	71.02	3093
HSA-MIR-548G-5P	99.78	71.12	3085
HSA-MIR-548X-5P	99.78	71.12	3085
HSA-MIR-200A-5P	99.76	69.10	949
HSA-MIR-200B-5P	99.76	69.05	948
HSA-MIR-4766-5P	99.75	69.23	2662
HSA-MIR-33A-3P	99.70	70.27	3362

Cross-species orthologs

1 orthologs

Organism	Symbol	Gene ID
danio_rerio		ENSDARG00000099025

Paralogs (18): ZNF430 (ENSG00000118620), ZNF66 (ENSG00000160229), ZNF22 (ENSG00000165512), ZNF680 (ENSG00000173041), ZNF114 (ENSG00000178150), ZFP41 (ENSG00000181638), ZNF730 (ENSG00000183850), ZNF479 (ENSG00000185177), ZNF626 (ENSG00000188171), ZNF431 (ENSG00000196705), ZNF100 (ENSG00000197020), ZNF257 (ENSG00000197134), ZNF98 (ENSG00000197360), ZNF675 (ENSG00000197372), ZNF273 (ENSG00000198039), ZNF737 (ENSG00000237440), ZNF253 (ENSG00000256771), ZNF723 (ENSG00000268696)

Protein

Protein identifiers

Zinc finger protein 92 — Q03936 (reviewed: Q03936)

Alternative names: Zinc finger protein HTF12

All UniProt accessions (3): Q03936, C9IZS8, V9HVY7

UniProt curated annotations — full annotation on UniProt →

Function. May be involved in transcriptional regulation.

Subcellular location. Nucleus.

Similarity. Belongs to the krueppel C2H2-type zinc-finger protein family.

Isoforms (3)

UniProt ID	Names	Canonical?
Q03936-1	1	yes
Q03936-2	2
Q03936-3	3

RefSeq proteins (5): NP_001274461, NP_001274462, NP_001274463, NP_009070, NP_689839* (*=MANE)

Domains & families (InterPro)

ID	Name	Type
IPR001909	KRAB	Domain
IPR013087	Znf_C2H2_type	Domain
IPR036051	KRAB_dom_sf	Homologous_superfamily
IPR036236	Znf_C2H2_sf	Homologous_superfamily

Pfam: PF00096, PF01352

UniProt features (24 total): zinc finger region 16, sequence variant 3, splice variant 2, chain 1, domain 1, sequence conflict 1

Structure

Experimental structures (PDB)

0 structures.

Predicted structure (AlphaFold)

Model	pLDDT	Fraction very-high
AF-Q03936-F1	71.94	0.10

Function

Pathways and Gene Ontology

Reactome pathways

1 pathways

ID	Pathway
R-HSA-212436	Generic Transcription Pathway

MSigDB gene sets: 74 (showing top): GSE18804_SPLEEN_MACROPHAGE_VS_BRAIN_TUMORAL_MACROPHAGE_UP, GSE45365_CTRL_VS_MCMV_INFECTION_NK_CELL_DN, RODRIGUES_THYROID_CARCINOMA_ANAPLASTIC_UP, DODD_NASOPHARYNGEAL_CARCINOMA_UP, FISCHER_DREAM_TARGETS, chr7q11, DOUGLAS_BMI1_TARGETS_UP, ACEVEDO_METHYLATED_IN_LIVER_CANCER_DN, GOMF_SEQUENCE_SPECIFIC_DNA_BINDING, SENGUPTA_NASOPHARYNGEAL_CARCINOMA_UP, GOBP_NEGATIVE_REGULATION_OF_TRANSCRIPTION_BY_RNA_POLYMERASE_II, GOBP_NEGATIVE_REGULATION_OF_NUCLEOBASE_CONTAINING_COMPOUND_METABOLIC_PROCESS, GOMF_TRANSCRIPTION_REGULATOR_ACTIVITY, ASH1L_TARGET_GENES, RYBP_TARGET_GENES

GO Biological Process (2): negative regulation of transcription by RNA polymerase II (GO:0000122), regulation of DNA-templated transcription (GO:0006355)

GO Molecular Function (7): RNA polymerase II cis-regulatory region sequence-specific DNA binding (GO:0000978), DNA-binding transcription factor activity, RNA polymerase II-specific (GO:0000981), DNA-binding transcription factor activity (GO:0003700), zinc ion binding (GO:0008270), DNA binding (GO:0003677), protein binding (GO:0005515), metal ion binding (GO:0046872)

GO Cellular Component (1): nucleus (GO:0005634)

Reactome top-level categories

Rollup of top-1 pathways:

Category	Pathways
RNA Polymerase II Transcription	1

GO top-level categories

Rollup of top GO terms by namespace:

Category	Terms
regulation of transcription by RNA polymerase II	2
RNA polymerase II transcription regulatory region sequence-specific DNA binding	2
transcription by RNA polymerase II	1
negative regulation of DNA-templated transcription	1
DNA-templated transcription	1
regulation of gene expression	1
regulation of RNA biosynthetic process	1
cis-regulatory region sequence-specific DNA binding	1
chromatin	1
DNA-binding transcription factor activity	1
transcription cis-regulatory region binding	1
regulation of DNA-templated transcription	1
transcription regulator activity	1
transition metal ion binding	1
nucleic acid binding	1
binding	1
cation binding	1
intracellular membrane-bounded organelle	1

Protein interactions and networks

STRING

598 interactions, top by confidence (×1000):

Protein A	Protein B	Partner UniProt	Score
ZNF92	TACSTD2	P09758	725
ZNF92	MLX	Q9UH92	644
ZNF92	LHFPL7	Q6ICI0	493
ZNF92	CREB1	P16220	427
ZNF92	PPP2R5C	Q13362	409
ZNF92	KRTAP1-1	Q07627	372
ZNF92	OR5H14	A6NHG9	370
ZNF92	NTRK1	P04629	359
ZNF92	ERVV-1	B6SEH8	356
ZNF92	ERVMER34-1	Q9H9K5	331
ZNF92	CLHC1	Q8NHS4	323
ZNF92	CIROZ	Q8N9H9	321
ZNF92	KRTAP1-5	Q9BYS1	314
ZNF92	OR5A1	Q8NGJ0	311
ZNF92	ZNF43	P17038	309

IntAct

61 interactions, top by confidence:

A	B	Type	Score
SDC2	PDPK1	psi-mi:“MI:0914”(association)	0.640
ZNF92	MEOX2	psi-mi:“MI:0915”(physical association)	0.560
TRIM28	ZNF316	psi-mi:“MI:0914”(association)	0.530
TRIM44	ODAD3	psi-mi:“MI:0914”(association)	0.530
RPS3	ZNF316	psi-mi:“MI:0914”(association)	0.530
ZNF707	ZNF316	psi-mi:“MI:0914”(association)	0.530
ZNF169	ZNF316	psi-mi:“MI:0914”(association)	0.530
ZNF324B	ZNF316	psi-mi:“MI:0914”(association)	0.530
H1-6	ZNF724	psi-mi:“MI:0914”(association)	0.530
TIMM50	ZNF724	psi-mi:“MI:0914”(association)	0.530
KLHL40	CBX4	psi-mi:“MI:0914”(association)	0.530
MAGEB2	POLRMT	psi-mi:“MI:0914”(association)	0.530
ZNF223	CENPB	psi-mi:“MI:0914”(association)	0.530
ZNF764	SH3PXD2B	psi-mi:“MI:0914”(association)	0.530
TRIM28	ZNF320	psi-mi:“MI:0914”(association)	0.530
ZNF92	GAPDH	psi-mi:“MI:0915”(physical association)	0.400
CREB1	ZNF92	psi-mi:“MI:0915”(physical association)	0.370
STAT6	ZNF92	psi-mi:“MI:0915”(physical association)	0.370
ECE1	ZNF92	psi-mi:“MI:0915”(physical association)	0.370
RPL27A	ZNF320	psi-mi:“MI:0914”(association)	0.350
PURG	ZNF320	psi-mi:“MI:0914”(association)	0.350
ZNF467	ZNF320	psi-mi:“MI:0914”(association)	0.350
FBLN5	ZNF320	psi-mi:“MI:0914”(association)	0.350
ZKSCAN8	ZNF320	psi-mi:“MI:0914”(association)	0.350
NOP2	ZNF320	psi-mi:“MI:0914”(association)	0.350
NOTCH2	ZNF320	psi-mi:“MI:0914”(association)	0.350
ZNF460	ZNF320	psi-mi:“MI:0914”(association)	0.350
LTBP2	ZNF320	psi-mi:“MI:0914”(association)	0.350
SPANXN2	ZNF320	psi-mi:“MI:0914”(association)	0.350
ZNF550	MEIOC	psi-mi:“MI:0914”(association)	0.350

BioGRID (73): ZNF92 (Affinity Capture-MS), ZNF92 (Affinity Capture-MS), ZNF92 (Affinity Capture-MS), ZNF92 (Affinity Capture-MS), ZNF92 (Affinity Capture-MS), ZNF92 (Affinity Capture-MS), ZNF92 (Affinity Capture-MS), ZNF92 (Affinity Capture-MS), ZNF92 (Affinity Capture-MS), ZNF92 (Affinity Capture-MS), ZNF92 (Affinity Capture-MS), ZNF92 (Affinity Capture-MS), ZNF92 (Affinity Capture-MS), ZNF92 (Affinity Capture-MS), ZNF92 (Affinity Capture-MS)

ESM2 similar proteins: A6NK75, A6NNF4, A6NP11, A8MTY0, B4DXR9, C9JN71, O75346, O75373, O75437, O95780, P0CJ79, P0DKX0, P0DPD5, P17017, P17019, P17035, P17038, P35789, Q03923, Q03924, Q03936, Q03938, Q08AN1, Q5MCW4, Q5R9F0, Q5SXM1, Q68DY1, Q6JLC9, Q6P5C7, Q6ZMV8, Q6ZN06, Q6ZN08, Q6ZNA1, Q6ZNG1, Q76KX8, Q86V71, Q86XN6, Q8IYB9, Q8IYN0, Q8N4W9

Diamond homologs: A0A1W2PQL4, A6NK75, A6NN14, A6NNF4, A6NP11, A8MQ14, A8MTY0, A8MUV8, A8MXY4, B4DX44, B4DXR9, E9PYI1, O14628, O43345, O75290, O75346, O75373, O75437, O95780, P0CB33, P0DKX0, P0DPD5, P16373, P17019, P17038, P21506, P35789, P52736, P52738, P52744, Q03923, Q03924, Q03936, Q03938, Q05481, Q14586, Q14593, Q14929, Q15928, Q3KNS6

SIGNOR signaling

0 interactions.

Enriched among interaction partners

Reactome pathways and GO biological processes over-represented among this gene’s 76 IntAct physical interaction partners (hypergeometric vs the genome-wide background, BH-FDR, gene-set size 15–500, ranked by fold). A functional readout of the neighbourhood — distinct from this gene’s own memberships above, and biased toward well-studied / hub proteins, so read it as themes rather than proof.

Reactome pathways:

Pathway	Partners	Fold	FDR
Peptide chain elongation	6	14.9×	2e-04
Viral mRNA Translation	6	14.9×	2e-04
PELO:HBS1L and ABCE1 dissociate a ribosome on a non-stop mRNA	6	14.8×	2e-04
Selenocysteine synthesis	6	14.1×	2e-04
Eukaryotic Translation Termination	6	14.1×	2e-04
Nonsense Mediated Decay (NMD) independent of the Exon Junction Complex (EJC)	6	13.8×	2e-04
ZNF598 and the Ribosome-associated Quality Trigger (RQT) complex dissociate a ribosome stalled on a no-go mRNA	6	13.8×	2e-04
Formation of a pool of free 40S subunits	6	13.2×	2e-04

GO biological processes:

GO term	Partners	Fold	FDR
cytoplasmic translation	6	15.9×	1e-03

Disease & clinical

Clinical variants and AI predictions

ClinVar

87 variants total. Per-class counts are floors (≥ shown; pagination cap):

Classification	Count (floor)
Pathogenic	0
Likely pathogenic	0
Uncertain significance	79
Likely benign	1
Benign	1

Top pathogenic / likely-pathogenic (0)

SpliceAI

611 predictions. Top by Δscore:

Variant	Effect	Δscore
7:65373966:C:G	donor_gain	1.0000
7:65374000:GGT:G	donor_loss	1.0000
7:65374001:GTGA:G	donor_loss	1.0000
7:65398337:TCAGT:T	acceptor_loss	1.0000
7:65398338:CAGTT:C	acceptor_loss	1.0000
7:65398339:A:AG	acceptor_gain	1.0000
7:65398339:AGTT:A	acceptor_loss	1.0000
7:65398340:G:GC	acceptor_gain	1.0000
7:65398340:GT:G	acceptor_gain	1.0000
7:65398340:GTT:G	acceptor_gain	1.0000
7:65398340:GTTA:G	acceptor_gain	1.0000
7:65398340:GTTAT:G	acceptor_gain	1.0000
7:65373987:G:GT	donor_gain	0.9900
7:65373999:TG:T	donor_gain	0.9900
7:65374000:GG:G	donor_gain	0.9900
7:65374001:G:GG	donor_gain	0.9900
7:65388801:AACAG:A	acceptor_loss	0.9900
7:65388803:CA:C	acceptor_loss	0.9900
7:65388804:AGGTA:A	acceptor_loss	0.9900
7:65388805:GGT:G	acceptor_gain	0.9900
7:65388898:CCAGG:C	donor_loss	0.9900
7:65388900:AGG:A	donor_loss	0.9900
7:65388901:GGTA:G	donor_loss	0.9900
7:65388902:G:GA	donor_loss	0.9900
7:65388903:TAGG:T	donor_loss	0.9900
7:65373998:ATG:A	donor_gain	0.9800
7:65388796:A:AG	acceptor_gain	0.9800
7:65388799:A:AG	acceptor_gain	0.9800
7:65388804:A:AG	acceptor_gain	0.9700
7:65388805:G:GG	acceptor_gain	0.9700

AlphaMissense

3925 scored. Top likely-pathogenic:

Variant	Protein change	am_pathogenicity
7:65399330:T:C	F406L	0.990
7:65399332:T:A	F406L	0.990
7:65399332:T:G	F406L	0.990
7:65398910:T:C	F266L	0.978
7:65398912:T:A	F266L	0.978
7:65398912:T:G	F266L	0.978
7:65399162:T:C	F350L	0.977
7:65399164:T:A	F350L	0.977
7:65399164:T:G	F350L	0.977
7:65399414:T:C	F434L	0.976
7:65399416:T:A	F434L	0.976
7:65399416:T:G	F434L	0.976
7:65399246:T:C	F378L	0.975
7:65399248:T:A	F378L	0.975
7:65399248:T:G	F378L	0.975
7:65398826:T:C	F238L	0.970
7:65398828:T:A	F238L	0.970
7:65398828:T:G	F238L	0.970
7:65399078:T:C	F322L	0.968
7:65399080:T:A	F322L	0.968
7:65399080:T:G	F322L	0.968
7:65399349:T:C	L412P	0.965
7:65398994:T:C	F294L	0.964
7:65398996:T:A	F294L	0.964
7:65398996:T:G	F294L	0.964
7:65387935:T:C	F13L	0.963
7:65387937:C:A	F13L	0.963
7:65387937:C:G	F13L	0.963
7:65399359:T:A	H415Q	0.961
7:65399359:T:G	H415Q	0.961

dbSNP variants (sampled 300 via entrez): RS1000028222 (7:65379380 T>C), RS1000106137 (7:65377994 G>C), RS1000115516 (7:65394599 T>C,G), RS1000160015 (7:65384625 C>T), RS1000301266 (7:65387393 C>G), RS1000311359 (7:65375580 T>C), RS1000385832 (7:65373017 A>G), RS1000523109 (7:65394160 T>A), RS1000582891 (7:65389297 A>G), RS1000648922 (7:65376931 G>A,T), RS1000660136 (7:65376583 A>G,T), RS1000762180 (7:65383197 T>G), RS1000921157 (7:65382809 C>G), RS1001080812 (7:65400558 A>G), RS1001297122 (7:65386072 T>C)

Disease associations

OMIM: gene MIM:603974 | disease phenotypes:

GenCC curated gene-disease

Mondo (1): primary ovarian failure (MONDO:0005387)

Orphanet (1): NON RARE IN EUROPE: Primary ovarian failure (Orphanet:619)

HPO phenotypes

0 total (0 of 0 shown, HPO-id order):

GWAS associations

0 associations (top):

MeSH disease descriptors (1)

Descriptor	Name	Tree numbers
D016649	Primary Ovarian Insufficiency	C12.050.351.500.056.630.750; C12.100.250.056.630.750; C19.391.630.750

Drugs & pharmacology

Drug and pharmacology data

Is drug target: no

PharmGKB: 1 entry (VIP=true, CPIC=false)

CTD chemical–gene interactions

37 total (human), top 30 by PubMed support.

Chemical	Actions (top 5)	PubMed papers
sodium arsenite	increases expression, decreases expression, increases abundance	4
Valproic Acid	decreases expression	3
perfluorooctane sulfonic acid	decreases expression	2
Arsenic	decreases expression, increases abundance, increases expression	2
Formaldehyde	decreases expression, increases expression	2
Tobacco Smoke Pollution	increases expression, decreases expression	2
3-((6-(2-methoxyphenyl)pyrimidin-4-yl)amino)phenyl)methane sulfonamide	decreases expression	1
TAK-243	affects sumoylation	1
dicrotophos	decreases expression	1
triphenyl phosphate	affects expression	1
2-methyl-4-isothiazolin-3-one	increases expression	1
manganese chloride	increases abundance, increases expression	1
pinosylvin	decreases expression	1
di-n-butylphosphoric acid	affects expression	1
abrine	decreases expression	1
licochalcone B	increases expression	1
jinfukang	decreases expression	1
2,3,5-trichloro-6-phenyl-(1,4)benzoquinone	increases expression	1
Bortezomib	increases expression	1
Sunitinib	decreases expression	1
Air Pollutants	decreases expression, increases abundance	1
Benzo(a)pyrene	decreases methylation	1
Cisplatin	decreases expression	1
Coal	decreases expression, increases abundance	1
Dimethyl Sulfoxide	increases expression	1
Doxorubicin	decreases expression	1
Ethyl Methanesulfonate	increases expression	1
Gold	decreases expression	1
Manganese	increases abundance, increases expression	1
Methyl Methanesulfonate	increases expression	1

Clinical trials (associated diseases)

75 trials via MONDO — disease-level, not drug-specific.

Trial	Phase	Status	Title
NCT00417066	PHASE4	COMPLETED	Flexible GnRH Antagonist vs Flare up GnRH Agonist Protocol in Poor Responders
NCT00732693	PHASE4	COMPLETED	Evaluation of Physiologic and Standard Sex Steroid Replacement Regimens in Women With Premature Ovarian Failure
NCT00837616	PHASE4	COMPLETED	Estrogen Dosing in Turner Syndrome: Pharmacology and Metabolism
NCT01853501	PHASE4	UNKNOWN	Effects of ADSC Therapy in Women With POF
NCT02783937	PHASE4	COMPLETED	Filgrastim for Premature Ovarian Insufficiency
NCT03535480	PHASE4	UNKNOWN	Autologous Bone Marrow Stem Cell Ovarian Transplantation to Restore Ovarian Function in Premature Ovarian Failure
NCT00140998	PHASE3	COMPLETED	Estrogen Treatment (Oral vs. Patches) in Turner Syndrome
NCT00001951	PHASE2	COMPLETED	Hormone Replacement in Young Women With Premature Ovarian Failure
NCT00370019	PHASE2	WITHDRAWN	Effects of an Estrogen Replacement Therapy Skin Patch on Ovulation in Women With Premature Ovarian Failure
NCT00429494	PHASE2	COMPLETED	GnRH Analogue for Ovarian Function Preservation in Hematopoietic Stem Cell Transplantation Patients
NCT03816852	PHASE2	SUSPENDED	The Safety and Efficiency Study of Mesenchymal Stem Cell (19#iSCLife®-POI) in Premature Ovarian Insufficiency
NCT04536467	PHASE2	UNKNOWN	Prevention of Chemotherapy-Induced Ovarian Failure With Goserelin in Premenopausal Lymphoma Patients
NCT06117982	PHASE2	COMPLETED	The Impact of Granulocyte Colony Stimulating Factor on Premature Ovarian Insufficiency
NCT02912104	PHASE1	COMPLETED	A Therapeutic Trial of Human Amniotic Epithelial Cells Transplantation for Primary Ovarian Failure
NCT03178695	PHASE1	COMPLETED	Inovium Ovarian Rejuvenation Trials
NCT04815213	PHASE1	ACTIVE_NOT_RECRUITING	The Use of Expandeded Mesenchymal Stromal Cells (MSC) in Premature Ovarian Failure (POF) in Adult Humans
NCT05138367	PHASE1	COMPLETED	Effects of UCA-PSCs in Women With POF
NCT06132542	PHASE1	UNKNOWN	Autologous ADMSC Transplantation in Patients With POI
NCT00948857	PHASE2/PHASE3	TERMINATED	Dehydroepiandrosterone (DHEA) Treatment and Premature Ovarian Failure (POF)
NCT04031456	PHASE2/PHASE3	RECRUITING	Autologous PRP Infusion May Restore Ovarian Function and May Promote Folliculogenesis in POI Patients
NCT02043743	PHASE1/PHASE2	UNKNOWN	Autologous Stem Cells Transplantation in Patients With Idiopathic and Drug Induced Premature Ovarian Failure
NCT02062931	PHASE1/PHASE2	UNKNOWN	Autologous Mesenchymal Stem Cells Transplantation In Women With Premature Ovarian Failure
NCT02151890	PHASE1/PHASE2	COMPLETED	Pregnancy After Stem Cell Transplantation in Premature Ovarian Failure
NCT02372474	PHASE1/PHASE2	COMPLETED	It is a Real The First Baby Of Autologous Stem Cell Therapy in Premature Ovarian Failure
NCT02603744	PHASE1/PHASE2	UNKNOWN	Autologous Adipose Derived Mesenchymal Stromal Cells Transplantation in Women With Premature Ovarian Failure (POF)
NCT02644447	PHASE1/PHASE2	COMPLETED	Transplantation of HUC-MSCs With Injectable Collagen Scaffold for POF
NCT03069209	PHASE1/PHASE2	UNKNOWN	Autologous Bone Marrow-Derived Stem Cell Transplantation in Patients With Premature Ovarian Failure (POF)
NCT03985462	PHASE1/PHASE2	WITHDRAWN	Very Small Embryonic-like Stem Cells for Ovary
NCT04009473	PHASE1/PHASE2	UNKNOWN	Stem Cell Therapy and Growth Factor Ovarian in Vitro Activation
NCT04071574	PHASE1/PHASE2	COMPLETED	Comparative Study on the Efficacy of Ovarian Stimulation Protocols on the Success Rate of ICSI in Female Infertility
NCT04922398	PHASE1/PHASE2	UNKNOWN	Ovarian Injection of PRP (Platelet -Rich Plasma) Vs Normal Saline in Premature Ovarian Insufficiency
NCT05462379	PHASE1/PHASE2	ACTIVE_NOT_RECRUITING	Autologous Heterotopic Fresh Ovarian Graft in Woman With LACC Eligible for Pelvic Radiotherapy Treatment.
NCT06202547	PHASE1/PHASE2	UNKNOWN	Intra-ovarian Injection of MSC-EVs in Idiopathic Premature Ovarian Failure
NCT01129947	EARLY_PHASE1	WITHDRAWN	The Use of DHEA in Women With Premature Ovarian Failure
NCT05522634	EARLY_PHASE1	UNKNOWN	A Clinical Study of Chinese Herbal Compound TJAOA101 in the Treatment of Premature Ovarian Insufficiency
NCT07308327	EARLY_PHASE1	ACTIVE_NOT_RECRUITING	The Influence of Gut Microbiota on Ovarian Function: A Single-center, Randomized,Double Blind, Parallel-controlled, Exploratory Clinical Trial
NCT00001275	Not specified	COMPLETED	Ovarian Follicle Function in Patients With Primary Ovarian Failure
NCT00001306	Not specified	COMPLETED	Steroid Therapy in Autoimmune Premature Ovarian Failure
NCT00006156	Not specified	COMPLETED	Feasibility Study for Development of an Early Test for Ovarian Failure
NCT00119925	Not specified	UNKNOWN	‘SPRING’-Study: Subfertility Guidelines: Patient Related Implementation in the Netherlands Among Gynaecologists